Advertisement

Medications for Chronic Conditions and Periodontal Disease

  • G. Rutger PerssonEmail author
Systemic Diseases (N Buduneli, Section Editor)
  • 6 Downloads
Part of the following topical collections:
  1. Topical Collection on Systemic Diseases

Abstract

Purpose of the Review

This study aims to review the current literature and consider the use of medication in the medical literature and medication in the treatment of periodontal inflammation. Review articles and non-human studies were avoided. Pain-killers and antibiotics were not covered. Modified tetracycline was, however, included. Non-surgical periodontal therapy remains standard of care procedure in the management of periodontal inflammation.

Recent Findings

There is a large volume of publications with findings from adjunct treatment of periodontitis using non-steroidal anti-inflammatory drugs, also including aspirin. In recent years (2015–2018), there are with the exception of in vitro and animal studies. There are currently few human studies assessing the safety and efficacy of such medication to treat periodontal inflammation alone. In contrast, the medical literature has a large volume of such studies to control inflammatory processes. Foremost, studies primarily on cardiovascular diseases, rheumatoid arthritis, and osteoporosis have contributed information on the use of statins, bisphosphonates, cytokine inhibitors, and prednisone in the management of inflammation. Several of these studies have also identified that patients on such medication may benefit from reduced clinical evidence of periodontal inflammation. Due to side effects from many anti-inflammatory medications sole treatment of periodontal inflammation has yet to be considered. Diet rich in flavonoids may also provide potential benefits in the control of periodontal inflammation.

Summary

There is currently no scientific evidence to suggest anti-inflammatory treatment of periodontal inflammation. There are in vitro and non-human studies suggesting that some anti-inflammatory drugs may be effective in reducing the extent of periodontal inflammation. It should be recognized that patients under medical care may receive added dental benefits as the result of anti-inflammatory treatment of another systemic disease.

Keywords

Medication Periodontal disease Inflammation Review 

Notes

Compliance with Ethical Standards

Conflict of Interest

G. Rutger Persson declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Schluger S. Osseous resection; a basic principle in periodontal surgery. Oral Surg Oral Med Oral Pathol. 1949;2:316–25.CrossRefGoogle Scholar
  2. 2.
    Löe H. Present day status and direction for future research on the etiology and prevention of periodontal disease. J Periodontol. 1969;40:678–82.CrossRefGoogle Scholar
  3. 3.
    Glickman I. Preventive periodontics-a blueprint for the periodontal health of the American public. J Periodontol. 1967;38:361–8.CrossRefGoogle Scholar
  4. 4.
    Ramfjord SP. The role of dental health education and auxillary personnel in the prevention of periodontal disease. Int Dent J. 1973;23:304–9.PubMedGoogle Scholar
  5. 5.
    Bronstein LH. Penicillin in the treatment of Vincent's angina. NY State J Med. 1946;46:735.Google Scholar
  6. 6.
    Moore DS. Penicillin; its use for the treatment of Vincent's infection. J Can Dent Assoc (Tor). 1945;11:543–52.Google Scholar
  7. 7.
    Benjamin SD, Hyman HM, Saffro DW. A study of the effects of antibiotics on the oral flora at the side of periodontal surgery in humans. J Periodontol. 1968;39:43.PubMedGoogle Scholar
  8. 8.
    Löe H, Schiott CR. The effect of mouthrinses and topical application of chlorhexidine on the development of dental plaque and gingivitis in man. J Periodontal Res. 1970;5:79–83.CrossRefGoogle Scholar
  9. 9.
    Lamont RJ, El-Sabaeny A, Park Y, Cook GS, Costerton JW, Demuth DR. Role of the Streptococcus gordonii SspB protein in the development of Porphyromonas gingivalis biofilms on streptococcal substrates. Microbiology. 2002;148(Pt 6):1627–36.CrossRefGoogle Scholar
  10. 10.
    Schaudinn C, Gorur A, Keller D, Sedghizadeh PP, Costerton JW. Periodontitis: an archetypical biofilm disease. Am Dent Assoc. 2009;140(8):978–86.CrossRefGoogle Scholar
  11. 11.
    Verma D, Garg PK, Dubey AK. Insights into the human oral microbiome. Arch Microbiol. 2018;20:525–40.CrossRefGoogle Scholar
  12. 12.
    Page RC, Schroeder HE. Pathogenesis of inflammatory periodontal disease. A summary of current work. Lab Investig. 1976;34:235–49.PubMedGoogle Scholar
  13. 13.
    Masada MP, Persson R, Kenney JS, Lee SW, Page RC, Allison AC. Measurement of interleukin-1 alpha and −1 beta in gingival crevicular fluid: implications for the pathogenesis of periodontal disease. J Periodontal Res. 1990;25:156–63.CrossRefGoogle Scholar
  14. 14.
    Kinane DF, Stathopoulou PG, Papapanou PN. Periodontal diseases. Nat Rev Dis Primers. 2017;3:17038.  https://doi.org/10.1038/nrdp.2017.38.CrossRefPubMedGoogle Scholar
  15. 15.
    Persson GR, Engel D, Whitney C, Darveau R, Weinberg A, Brunsvold M, et al. Immunization against Porphyromonas gingivalis inhibits progression of experimental periodontitis in nonhuman primates. Infect Immun. 1994;62:1026–31.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Ebersole J, Holt SC, Hansard R, Novak MJ. Microbiologic and immunologic characteristics of periodontal disease in Hispanic americans with type 2 diabetes. J Periodontol. 2008;79:637–46.CrossRefGoogle Scholar
  17. 17.
    Williams RC, Offenbacher S. Periodontal medicine: The emergence of a new branch of periodontology. Periodontol. 2000;23:9–12.CrossRefGoogle Scholar
  18. 18.
    Alyousef AA, Divakar DD, Muzaheed. Chemically modified tetracyclines an emerging host modulator in chronic periodontitis patients: A randomized, double-blind, placebo-controlled, clinical trial. Microb Pathog. 2017;110:279–84.CrossRefGoogle Scholar
  19. 19.
    Golub LM, Elburki MS, Walker C, Ryan M, Sorsa T, Tenenbaum H, et al. Non-antibacterial tetracycline formulations: host-modulators in the treatment of periodontitis and relevant systemic diseases. Int Dent J. 2016;66:127–35.CrossRefGoogle Scholar
  20. 20.
    Madi M, Pavlic V, Samy W, Alagl A. The anti-inflammatory effect of locally delivered nano-doxycycline gel in therapy of chronic periodontitis. Acta Odontol Scand. 2018;76:71–6.CrossRefGoogle Scholar
  21. 21.
    Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol. 2018;15:757–69.  https://doi.org/10.1038/s41569-018-0098-5.CrossRefPubMedGoogle Scholar
  22. 22.
    Tuñón J, Bäck M, Badimón L, Bochaton-Piallat ML, Cariou B, Daemen MJ, et al. Hoefer IE; ESC working group on atherosclerosis and vascular biology. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: translating experimental targets into clinical practice. Eur J Prev Cardiol. 2018;25:948–55.CrossRefGoogle Scholar
  23. 23.
    • Sayar F, Fallah S, Akhondi N, Jamshidi S. Association of serum lipid indices and statin consumption with periodontal status. Oral Dis. 2016;22:775–80 This a large study showing evidence on the efficacy of statins in individuals with hyperlipidemia and the association between periodontal status (inflammation) and the lipid profile. CrossRefGoogle Scholar
  24. 24.
    •• Cicek Ari V, Ilarslan YD, Erman B, Sarkarati B, Tezcan I, Karabulut E, et al. Inflammation. 2016;39:1547–57 This well-designed large study identified treatment with statins may prevent the progression of periodontitis while reducing the extent of periodontal inflammation expressed by cytokine levels and clinical findings. CrossRefGoogle Scholar
  25. 25.
    • Pradeep AR, Kumari M, Rao NS, Martande SS, Naik SB. Clinical efficacy of subgingivally delivered 1.2% atorvastatin in chronic periodontitis: a randomized controlled clinical trial. J Periodontol. 2013;84:871–9 This is well-designed longitudinal randomized clinical trial to suggest that adjunct treatment with atorvastatin provide benefits in reducing the extent of periodontal inflammation. CrossRefGoogle Scholar
  26. 26.
    Estanislau IM, Terceiro IR, Lisboa MR, Teles Pde B, Carvalho Rde S, Martins RS, et al. Pleiotropic effects of statins on the treatment of chronic periodontitis--a systematic review. Br J Clin Pharmacol. 2015;79:877–85.CrossRefGoogle Scholar
  27. 27.
    Rosenberg DR, Andrade CX, Chaparro AP, Inostroza CM, Ramirez V, Violant D, et al. Short-term effects of 2% atorvastatin dentifrice as an adjunct to periodontal therapy: a randomized double-masked clinical trial. J Periodontol. 2015;86:623–30.CrossRefGoogle Scholar
  28. 28.
    Kumari M, Martande SS, Pradeep AR, Naik SB. Efficacy of Subgingivally Delivered 1.2% Atorvastatin in the Treatment of Chronic Periodontitis in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Clinical Trial. J Periodontol. 2016;87:1278–85.CrossRefGoogle Scholar
  29. 29.
    Poston CJ, Pierce TC, Li Y, Brinson CW, Lu Z, Lauer AW, et al. Statin intake is associated with MMP-1 level in gingival crevicular fluid of patients with periodontitis. Oral Dis. 2016;22:438–44.CrossRefGoogle Scholar
  30. 30.
    Martande S, Kumari M, Pradeep AR, Pal Singh S, Kumar SD. Comparative evaluation of efficacy of subgingivally delivered 1.2% atorvastatin and 1.2% simvastatin in the treatment of intrabony defects in chronic periodontitis: a randomized controlled trial. J Dent Res Dent Clin Dent Prospects. 2017;11(1):18–25.CrossRefGoogle Scholar
  31. 31.
    Bieri RA, Adriaens L, Spörri S, Lang NP, Persson GR. Gingival fluid cytokine expression and subgingival bacterial counts during pregnancy and postpartum: a case series. Clin Oral Investig. 2013;17:19–28.CrossRefGoogle Scholar
  32. 32.
    Kobayashi T, Ito S, Kobayashi D, Kojima A, Shimada A, Narita I, et al. Interleukin-6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors. Clin Exp Dent Res. 2015;13;1:63–73.CrossRefGoogle Scholar
  33. 33.
    Alkadasi B, Abdulrab S, Gaafer S, Kalakonda B, Hosny M, Shaker O, et al. Effect of adjunctive use of systemic antioxidant therapy (N-acetylcysteine) on soluble receptor activator nuclear factor κB ligand levels in gingival crevicular fluid following surgical periodontal treatment for chronic periodontitis. J Oral Sci. 2017;59:519–26.CrossRefGoogle Scholar
  34. 34.
    Axelsson KF, Wallander M, Johansson H, Lundh D, Lorentzon M. Hip fracture risk and safety with alendronate treatment in the oldest-old. J Intern Med. 2017;282:546–59.CrossRefGoogle Scholar
  35. 35.
    Buduneli E, Vardar S, Buduneli N, Berdeli AH, Türkoğlu O, Başkesen A, et al. Effects of combined systemic administration of low-dose doxycycline and alendronate on endotoxin-induced periodontitis in rats. J Periodontol. 2004;75:1516–23.CrossRefGoogle Scholar
  36. 36.
    Chen J, Chen Q, Hu B, Wang Y, Song J. Effectiveness of alendronate as an adjunct to scaling and root planing in the treatment of periodontitis: a meta-analysis of randomized controlled clinical trials. J Periodontal Implant Sci. 2016;46:382–95.CrossRefGoogle Scholar
  37. 37.
    Lerner UH. Inflammation-induced bone remodelingin periodontal disease and the influence of post-menopausal osteoporosis. J Dent Res. 2006;85:596–07.CrossRefGoogle Scholar
  38. 38.
    Nagasawa T, Kiji M, Yashiro R, Hormdee D, Lu H, Kunze M, et al. Roles of receptor activator of nuclear factor-κBligand (RANKL) and osteoprotegerin in periodontal health and disease. Periodontol 2000. 2007;43:65–84.CrossRefGoogle Scholar
  39. 39.
    Özden FO, Sakallioğlu EE, Demir E, Bilgici B, Tunçel ÖK, Gökosmanoğlu F, et al. Effect of bisphosphonate as an adjunct treatment for chronic periodontitis on gingival crevicuar fluid levels of nuclear factor-κB ligand (RANKL) and osteoprotegerin in postmenopausal osteoporosis. J Oral Sci. 2017;59:147–55.CrossRefGoogle Scholar
  40. 40.
    Ziebolz D, Rupprecht A, Schmickler J, Bothmann L, Krämer J, Patschan D, et al. Association of different immunosuppressive medications with periodontal condition in patients with rheumatoid arthritis: results from a cross-sectional study. J Periodontol. 2018;89:1310–7.CrossRefGoogle Scholar
  41. 41.
    Beyer K, Zaura E, Brandt B, Buijs MJ, Brun JG, Crielaard W, et al. Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health. PLoS One. 2018;13(9):e0202278.  https://doi.org/10.1371/journal.pone.0202278 eCollection 2018.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Bello-Gualtero JM, Lafaurie GI, Hoyos LX, Castillo DM, De-Avila J, Munevar JC, et al. Periodontal disease in individuals with a genetic risk of developing arthritis and early rheumatoid arthritis: a cross-sectional study. J Periodontol. 2016;87:346–56.CrossRefGoogle Scholar
  43. 43.
    Kurgan Ş, Önder C, Balcı N, Fentoğlu Ö, Eser F, Balseven M, et al. Gingival crevicular fluid tissue/blood vessel-type plasminogen activator and plasminogen activator inhibitor-2 levels in patients with rheumatoid arthritis: effects of nonsurgical periodontal therapy. J Periodontal Res. 2017;52:574–81.CrossRefGoogle Scholar
  44. 44.
    Cosgarea R, Tristiu R, Dumitru RB, Arweiler NB, Rednic S, Sirbu CI, et al. Effects of non-surgical periodontal therapy on periodontal laboratory and clinical data as well as on disease activity in patients with rheumatoid arthritis. Clin Oral Investig. 2018.  https://doi.org/10.1007/s00784-018-2420-3.
  45. 45.
    Yang NY, Wang CY, Chyuan IT, Wu KJ, Tu YK, Chang CW, et al. Significant association of rheumatoid arthritis-related inflammatory markers with non-surgical periodontal therapy. J Formos Med Assoc. 2018;117:1003–10.CrossRefGoogle Scholar
  46. 46.
    Zhao X, Liu Z, Shu D, Xiong Y, He M, Xu S, et al. Association of Periodontitis with Rheumatoid Arthritis and the Effect of Non-Surgical Periodontal Treatment on Disease Activity in Patients with Rheumatoid Arthritis. Med Sci Monit. 2018;24:5802–10.CrossRefGoogle Scholar
  47. 47.
    Alvarez-Suarez JM, Giampieri F, Tulipani S, Casoli T, di Stefano G, Gonzalez-Paramas AM, et al. One-month strawberry-rich anthocyanin supplementation ameliorates cardiovascular risk, oxidative stress markers and platelet activation in humans. J Nutr Biochem. 2014;25:289–94.CrossRefGoogle Scholar
  48. 48.
    Daniels JA, Mulligan C, McCance D, Woodside JV, Patterson C, Young IS, et al. A randomised controlled trial of increasing fruit and vegetable intake and how this influences the carotenoid concentration and activities of PON-1 and LCAT in HDL from subjects with type 2 diabetes. Cardiovasc Diabetol. 2014;13:16.CrossRefGoogle Scholar
  49. 49.
    Widén C, Coleman M, Critén S, Karlgren-Andersson P, Renvert S, Persson GR. Consumption of Bilberries Controls Gingival Inflammation. Int J Mol Sci. 2015;16(5):10665–73.  https://doi.org/10.3390/ijms160510665.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Holmer H, Widén C, Wallin Bengtsson V, Coleman M, Wohlfart B, Steen S, Persson GR,, Sjöberg K. Improved General and Oral Health in Diabetic Patients by an Okinawan-Based Nordic Diet: A Pilot Study. Int J Mol Sci. 2018;19(7). pii: E1949.  https://doi.org/10.3390/ijms19071949.
  51. 51.
    Jauhiainen L, Suominen AL, Kanerva N, Männistö S, Knuuttila M. Ylöstalo P periodontal pocketing and gingival bleeding in relation to Nordic diet - results from a population-based survey. J Clin Periodontol. 2016;43:1013–23.CrossRefGoogle Scholar
  52. 52.
    Woelber JP, Bremer K, Vach K, König D, Hellwig E, Ratka-Krüger P, et al. An oral health optimized diet can reduce gingival and periodontal inflammation in humans - a randomized controlled pilot study. BMC Oral Health. 2016;26;17(1):28.  https://doi.org/10.1186/s12903-016-0257-1.CrossRefGoogle Scholar
  53. 53.
    Dodington DW, Fritz PC, Sullivan PJ, Ward WE. Higher intakes of fruits and vegetables, β-carotene, vitamin C, α-tocopherol, EPA, and DHA are positively associated with periodontal healing after nonsurgical periodontal therapy in nonsmokers but not in smokers. J Nutr. 2015;145:2512–9.CrossRefGoogle Scholar
  54. 54.
    Thanakun S, Pornprasertsuk-Damrongsri S, Izumi Y. Increased oral inflammation, leukocytes, and leptin, and lower adiponectin in overweight or obesity. Oral Dis. 2017;23:956–65.CrossRefGoogle Scholar
  55. 55.
    Ozen G, Boumiza S, Deschildre C, Topal G, Longrois D, Jakobsson PJ, et al. Inflammation increases MMP levels via PGE2 in human vascular wall and plasma of obese women. Int J Obes. 2018.  https://doi.org/10.1038/s41366-018-0235-6.
  56. 56.
    Suvan JE, Finer N, D'Aiuto F. Periodontal complications with obesity. Periodontol 2000. 2018;78:98–28.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.University of WashingtonSeattleUSA
  2. 2.Oral Health SciencesUniversity of KristianstadKristianstadSweden

Personalised recommendations